LINCOLN PHARMACEUTICALS
|
The Current P/E Ratio of LINCOLN PHARMACEUTICALS is 14.04.
| Share Price | ₹616.6 | Feb 24,2026 |
| Market Cap | ₹1,233.2 Cr | |
| Earnings-TTM | ₹87.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 14.04x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of LINCOLN PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,233.2 Cr] as on Feb 24,2026
(/) Earnings [ ₹87.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 14.04x ]
Thus, for LINCOLN PHARMACEUTICALS , the investors are currently willing to pay 14.04 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LINCOLN PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LINCOLN PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of LINCOLN PHARMACEUTICALS
PE Ratio Performance Analysis for LINCOLN PHARMACEUTICALS
- LINCOLN PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 10.30x.
- LINCOLN PHARMACEUTICALS 's operated at median p/e ratio of 9.31x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LINCOLN PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 13.42x.
- LINCOLN PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2021 of 7.23x.
How does LINCOLN PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| LINCOLN PHARMACEUTICALS | 87.83 | 14.04 | 1,233.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 37.74 | 415,217.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 66.98 | 166,047.0 |
| CIPLA LTD | 4,544.70 | 23.57 | 107,136.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 65.52 | 148,872.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.69 | 108,454.0 |
| MANKIND PHARMA LTD | 1,796.65 | 47.18 | 84,767.5 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.44 | 90,998.8 |
| LUPIN LTD | 4,669.18 | 22.03 | 102,885.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 19.26 | 67,654.7 |
| ABBOTT INDIA LTD | 1,524.13 | 36.73 | 55,976.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LINCOLN PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 14.04x |
| Max industry PE | 66.98x |
| Median industry PE | 23.57x |
| Average industry PE | 33.74x |
You may also like the below Video Courses